Slowing the progression of Alzheimer’s disease; what works?
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is an age-related progressive dementia, which is increasing in prevalence world-wide. Typically affecting short-term memory at onset, this devastating illness advances to impair all aspects of cognition, as well as non-cognitive domains. Although much effort has been made in recent years to develop disease-modifying treatments, medications which provided promising results in pre-clinical research have so far faltered in human clinical trials. Attention has recently shifted into trying to identify preventative measures that may delay the onset of the illness. Preventative factors include physical activity, proper diet, cognitive stimulation and the management of conditions such as hypertension, diabetes and obesity. However, it remains imperative to identify approaches that may help patients already diagnosed with the illness. Alongside pharmacological research, much work has been done on uncovering strategies which may slow down the progression of AD. This review aims to summarize evidence supporting or refuting methods impacting on the progression of the disease. AD remains a chronic and serious condition, therefore any intervention delaying the onset of moderate/severe symptoms will have a significant impact on patients and their families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 1×
“While cognitive reserve may have a protective effect against early presentation of symptoms, this may be lost once conditions advance, as higher levels of cognitive reserve mask the consequences of early pathology (Stern, 2012).”
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · cited 1×
“Little difference has been found between the three AChEIs in regards to their effectiveness (Birks, 2006).”
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Disease-modifying drug treatments remain evasive, and AD has one of the lowest success rates for drug approval into Phase three testing (Cummings et al. 2014).”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Cytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365
Influence of social network on occurrence of dementia: a community-based longitudinal study
Fratiglioni, L., Wang, H.-X., Ericsson, K., Maytan, M., & Winblad, B. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02113-9 · Cited by 1,361
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Passive immunization by injection of pre-made antibodies has showed promise in AD transgenic mouse models (DeMattos et al. 2001).”
Sunlight and Vitamin D: A global perspective for health
Wacker, M., & Holick, M. F. (2013) · Dermato-Endocrinology · doi:10.4161/derm.24494 · Cited by 1,156
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139
The age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118
Cognitive stimulation to improve cognitive functioning in people with dementia
Woods, B., Aguirre, E., Spector, A. E., & Orrell, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005562.pub2 · Cited by 855
FERRIS, L. T., WILLIAMS, J. S., & SHEN, C.-L. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31802f04c7 · Cited by 849 · cited 1×
“Brain derived neutrophic factor (BDNF) for instance, which facilitates neuronal survival, increases after acute exercise (Ferris et al. 2007).”
Review: microglia of the aged brain: primed to be activated and resistant to regulation
Norden, D. M., & Godbout, J. P. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01306.x · Cited by 792
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., Andrieu, S., Rivière, D., & Vellas, B. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01035.x · Cited by 661
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 1×
“Animal research suggests hypoxia treatment can increase expression of genes related to AD neuropathology (Sun et al. 2006) but this is yet to be clarified in humans.”
Depression as a Risk Factor for Alzheimer Disease: The MIRAGE Study
Green, R. C., Cupples, L. A., Kurz, A., Auerbach, S., Go, R., Sadovnick, D., Duara, R., Kukull, W. A., Chui, H., Edeki, T., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.753 · Cited by 551
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490
Sultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478 · cited 1×
“Oxidative stress has been proposed as one of the major causal factors of aging (De la Fuente 2002), with the brain being particularly susceptible to oxidative damage due to its high energy demand and oxygen consumption (Sultana et al. 2013).”
Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease
Stern, Y., Alexander, G. E., Prohovnik, I., & Mayeux, R. (1992) · Annals of Neurology · doi:10.1002/ana.410320311 · Cited by 470
Physical exercise and cognitive performance in the elderly: Current perspectives.
Kirk-Sanchez, N., & McGough, E. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39506 · Cited by 465
Deciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Neuroprotective and disease-modifying effects of the ketogenic diet
Gasior, M., Rogawski, M. A., & Hartman, A. L. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00009 · Cited by 445
Kohut, M. L., McCann, D. A., Russell, D. W., Konopka, D. N., Cunnick, J. E., Franke, W. D., Castillo, M. C., Reighard, A. E., & Vanderah, E. (2006) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.12.002 · Cited by 436
Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Whitmer, R., Gunderson, E., Quesenberry, C., Zhou, J., & Yaffe, K. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362047 · Cited by 430
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Tabet, N. (2006) · Age and Ageing · doi:10.1093/ageing/afl027 · Cited by 285 · cited 2×
“For instance, the effect of AChEIs upon the cholinergic system is well established, however their influence on the inflammatory system in the brain via nicotinic acetylcholine receptors is only recently becoming appreciated (Tabet, 2006).”
Self-citationImmunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“Another active Aβ vaccine aiming to target B-cell antigens is currently being investigated by Novartis Pharmaceuticals (Wisniewski & Goñi 2015).”
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · cited 1×
“Also, combination treatment was found to significantly reduce the risk of nursing home admission (Lopez et al. 2009). Rive et al., (2013) carried out a comprehensive review and comparison of meta-analyses of memantine treatment and showed a significant effect on cognitive decline and ADL in moderate to severe AD patie…”
Jacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., Albert, M., Brandt, J., & Stern, Y. (1994) · Neurology · doi:10.1212/wnl.44.7.1215 · Cited by 266
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen, J. S., Salmon, D. P., Thal, L. J., Romero, R., Weisstein–Jenkins, C., Galasko, D., Hofstetter, C. R., Thomas, R., Grant, I., & Jeste, D. V. (2000) · Neurology · doi:10.1212/wnl.54.10.1965 · Cited by 254
Stern, Y., Tang, M. X., Denaro, J., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370508 · Cited by 252
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250
Hassing, L. B. (2004) · Age and Ageing · doi:10.1093/ageing/afh100 · Cited by 249
Bahar-Fuchs, A., Clare, L., & Woods, B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt189 · Cited by 239 · cited 3×
“A Cochrane review of eleven RCTs was unable to find a positive effect of cognitive training in patients with dementia (Bahar-Fuchs et al. 2013). Alternatively, cognitive stimulation therapy (CST) offered in groups is designed to help stimulate cognitive engagement and social functioning. A major focus is on reality or…”
InfluentialLong-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · cited 1×
“Over a longer time frame of thirty months, memantine combination treatment has been shown to slow the decline in cognitive functioning and activities of daily living (ADL) greater than AChEI alone or no treatment (Atri et al. 2008).”
Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease
Praticò, D., & Sung, S. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6209 · Cited by 229 · cited 1×
“Increased levels of oxidation markers have been measured in cerebral spinal fluid of MCI and AD patients (Praticò & Sung 2004; Praticò et al. 2002).”
Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk
Devore, E. E., Grodstein, F., van Rooij, F. J., Hofman, A., Rosner, B., Stampfer, M. J., Witteman, J. C., & Breteler, M. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27037 · Cited by 205
Cognitive stimulation to improve cognitive functioning in people with dementia
Woods, B., Rai, H. K., Elliott, E., Aguirre, E., Orrell, M., & Spector, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005562.pub3 · Cited by 190
Bjelakovic, G., Nikolova, D., & Gluud, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074558 · Cited by 183 · cited 2×
“Indeed, high doses of vit E are associated with toxicity and should be used with caution (Bjelakovic et al. 2013). Vit E is a group of eight compounds, with α-tocopherol being most commonly studied in AD. A recent RCT however, did find significantly reduced decline in ADL with α-tocopherol treatment compared to placeb…”
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064971 · Cited by 160
Lopez, O. L., Becker, J. T., Chang, Y.-F., Sweet, R. A., Aizenstein, H., Snitz, B., Saxton, J., McDade, E., Kamboh, M. I., DeKosky, S. T., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12081046 · Cited by 129
Shah, R. C., Kamphuis, P. J., Leurgans, S., Swinkels, S. H., Sadowsky, C. H., Bongers, A., Rappaport, S. A., Quinn, J. F., Wieggers, R. L., Scheltens, P., et al. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt224 · Cited by 112
Sepehry, A. A., Lee, P. E., Hsiung, G. Y. R., Beattie, B. L., & Jacova, C. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0012-5 · Cited by 94
Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?
Luchsinger, J. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091687 · Cited by 91
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2583 · Cited by 66
Long-term progression of Alzheimer's disease in patients under antidementia drugs
Gillette‐Guyonnet, S., Andrieu, S., Nourhashemi, F., Gardette, V., Coley, N., Cantet, C., Gauthier, S., Ousset, P., Vellas, B., & REAL.FR study group (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.009 · Cited by 64
Gustafsson, P. E., Persson, M., & Hammarstrom, A. (2012) · The European Journal of Public Health · doi:10.1093/eurpub/ckr061 · Cited by 50 · cited 1×
“Such individuals are also more likely to be wealthier and more educated (Gustafsson et al. 2012; Atella & Kopinska 2014), which may influence reported results.”
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10
Cited by
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Neighborhood Environment and Cognition in Older Adults: A Systematic Review
Besser, L. M., McDonald, N. C., Song, Y., Kukull, W. A., & Rodriguez, D. A. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.02.013 · Cited by 268
Gosztolya, G., Vincze, V., Tóth, L., Pákáski, M., Kálmán, J., & Hoffmann, I. (2019) · Computer Speech & Language · doi:10.1016/j.csl.2018.07.007 · Cited by 196
Nutrition and AGE‐ing: Focusing on Alzheimer’s Disease
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7039816 · Cited by 103
Assessing Alzheimer’s disease from speech using the i-vector approach
Egas López, J. V., Tóth, L., Hoffmann, I., Kálmán, J., Pákáski, M., & Gosztolya, G. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-26061-3_30 · Cited by 18
“The early diagnosis of the disease could lead to a more effective confrontation of the AD in order to slow down its development; this stage of diagnosis is difficult to achieve [14,24].”
Background
Metadata
- Authors
- Nelson, L., & Tabet, N.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 23
- Issue
- Pt B
- Pages
- 193-209
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W1031113081
- Cited by
- 109
- References
- 60
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.